MarginsXMarginsX
Home › Markets › Health Care › MOLN

Molecular Partners AG (MOLN)

MOLN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.70
-8.21% on the day
Market cap
$101.2M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$73.5M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1745114/000174511426000009/0001745114-26-000009-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from CHF at 0.8384 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerMOLN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountrySwitzerland
IPO year2021
SEC CIK0001745114
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inSwitzerland

Financials · 2025

LineValue
Revenue$0
Net income-$73.5M
Operating income-$69.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$98.6M
Total assets$121.8M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Reported in CHF; shown in US dollars.

Warning signs

Cash runway
19.4 months
82.7M CHF cash at December 31, 2025
Share count, 1 year
0.0%
2024-12-31 to 2025-12-31 · +12.0% over 3 years
Going-concern doubt
No
20-F filed March 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-12
Cash and burn82.7M CHF cash; operating cash flow -12.8M CHF a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG AG, Zurich, SwitzerlandPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
0 CHF-61.7M CHF-51.3M CHF82.7M CHFNo debt tags0 CHF20-F 2026-03-12
FY 2024
2024-12-31
5.0M CHF-54.0M CHF-59.2M CHF63.9M CHFNo debt tags5.0M CHF20-F 2025-03-06
FY 2023
2023-12-31
7.0M CHF-62.0M CHF-59.0M CHF67.3M CHFNo debt tags7.0M CHF20-F 2025-03-06
FY 2022
2022-12-31
189.6M CHF117.9M CHF118.6M CHF87.9M CHFNo debt tags189.6M CHF20-F 2025-03-06
FY 2021
2021-12-31
9.8M CHF-63.8M CHF-91.0M CHF71.8M CHFNo debt tags9.8M CHF20-F 2024-03-14
FY 2020
2020-12-31
9.3M CHF-62.8M CHF-29.0M CHF133.7M CHFNo debt tags9.3M CHF20-F 2023-03-09
FY 2019
2019-12-31
20.4M CHF-36.3M CHF-1.2M CHF75.7M CHFNo debt tags20.4M CHF20-F 2022-03-15

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentF-32025-04-11
Latest annual report20-F2026-03-12
Latest quarterly / interim6-K2026-10-29

Source: SEC EDGAR submissions feed, 121 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.6%
1 month-19.9%
3 months-30.2%
Year to date-32.6%
1 year-31.3%
From 52-week high-42.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
ZURAZura Bio Limited$1.08-12.90%$104.0M
OTLKOutlook Therapeutics Inc.$0.3960-4.12%$96.4M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
BDTXBlack Diamond Therapeutics Inc.$1.53+4.08%$87.9M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier